{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:05Z","timestamp":1794047405535,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2021.279037","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T04:03:55Z","timestamp":1637208235000},"page":"740-743","source":"Crossref","is-referenced-by-count":19,"title":["Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen \u2013 a real world study on patients diagnosed in Sweden 2007-2017"],"prefix":"10.3324","volume":"107","author":[{"given":"Alexandra","family":"Albertsson-Lindblad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorgerdur","family":"Palsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Weibull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"34056","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow- up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020; 38(3):248-256.","DOI":"10.1200\/JCO.19.01294"},{"key":"34057","doi-asserted-by":"crossref","unstructured":"Geisler CH, Kolstad A, Laurell A. Long-term progressionfree survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008; 112(7):2687-2693.","DOI":"10.1182\/blood-2008-03-147025"},{"key":"34058","doi-asserted-by":"crossref","unstructured":"Hermine O, Hoster E, Walewski J. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016; 388(10044):565-575.","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"34059","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an openlabel, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"34060","doi-asserted-by":"crossref","unstructured":"Flinn IW, van der Jagt R, Kahl BS. Randomized trial of bendamustine- rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014; 123(19):2944-2952.","DOI":"10.1182\/blood-2013-11-531327"},{"key":"34061","unstructured":"Cancercentrumi samverkan R. Nationella kvalitetsregistret f\u00f6r lymfom - \u00c5rsrapport fr\u00e5n Nationell kvalitetsregistret f\u00f6r lymfom, diagnosperioden 2000-2019. 2020. Publisher Full Text|"},{"key":"34062","unstructured":"Royston P, Lambert PC. Flexible parametric survival analysis using stata: beyond the Cox model. 2011."},{"key":"34063","doi-asserted-by":"crossref","unstructured":"Villa D, Sehn LH, Savage KJ. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020; 4(15):3486-3494.","DOI":"10.1182\/bloodadvances.2020002068"},{"key":"34064","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Thieblemont C, Oberic L. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017; 377(13):1250-1260.","DOI":"10.1056\/NEJMoa1701769"},{"key":"34065","doi-asserted-by":"crossref","unstructured":"Zoellner AK, Unterhalt M, Stilgenbauer S. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021; 8(9):e648-e657.","DOI":"10.1016\/S2352-3026(21)00195-2"},{"key":"34066","doi-asserted-by":"crossref","unstructured":"Gerson JN, Handorf E, Villa D. Survival outcomes of younger patients with mantle cell lymphoma treated in the Rituximab era. J Clin Oncol. 2019; 37(6):471-480.","DOI":"10.1200\/JCO.18.00690"},{"key":"34067","doi-asserted-by":"crossref","unstructured":"Delfau-Larue M-H, Klapper W, Berger F. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015; 126(5):604-611.","DOI":"10.1182\/blood-2015-02-628792"},{"key":"34068","doi-asserted-by":"crossref","unstructured":"Eskelund CW, Dahl C, Hansen JW. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017; 130(17):1903-1910.","DOI":"10.1182\/blood-2017-04-779736"},{"key":"34069","doi-asserted-by":"crossref","unstructured":"Bernard M, Tsang RW, Le LW. Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma. 2013; 54(2):261-267.","DOI":"10.3109\/10428194.2012.711828"},{"key":"34070","doi-asserted-by":"crossref","unstructured":"Glimelius I, Smedby KE, Albertsson-Lindblad A. Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. Blood Adv. 2021; 5(6):1638-1647.","DOI":"10.1182\/bloodadvances.2020003645"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279037\/73861","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279037\/74211","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10452\/73861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:40Z","timestamp":1794045640000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279037","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}